CTAD 2026: AriBio’s Alzheimer’s candidate slows cognitive decline as monotherapy
At the 2026 Clinical Trials on Alzheimer’s Disease conference, AriBio reported that AR1001 slowed cognitive decline more than placebo in patients not taking other drugs for the disease.
comments(0)
5-min edit window · permanent after that